Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience

E Chapman, Louisa; J Mertz, Gregory; J Peters, Clarence; M Jolson, Heidi; S Khan, Ali; G Ksiazek, Thomas; T Koster, Frederick; F Baum, Kenneth; E Rollin, Pierre; T Pavia, Andrew; C Holman, Robert; C Christenson, John; J Rubin, Phillip; E Behrman, Rachel; J Wilson Bell, Linda; L Simpson, Gary; F Sadek, Ramses; Ribavirin Study Group, The; Armstrong, B; Atterbury, BT; Baacke, G; Bellardi, D; Carroll, M; Cheek, J; Craig, A; Daniels, D; Freeman, W; Held, F; Kessler, D; Konicck, S; Light, A; McGee, J; Savage, J; Sloan, M; Tempest, B; Vaughan, K; Waite, D; Becher, J; Brieman, R; Bulter, J; Schmidt-Dalton, MJ; Hart, DC; Hawk, J; Khabbaz, R; Lloyd, E; Sortir, M; Stokes, S; Torok, TJ; Vitek, C; Harding;, S; England, R; Kioski, C; Mosley, D; Sands, L; Johnson-Baach, T; Ronnau, KJ; Mast, DD; Servi, R; Levinson, R; Yeager, FS; Adam, R; Friedman, B; Lincoln, L; Petersen, EA; Wack, E; Moncada, R; Singh Bassi, S; Rumack, JS; Kuriyama, S; McGovern, J; Olson, D; Garst, P; Butera, ML; Erlich, K; Dinolfo, M; Dalton, C; Hoffman, R; Kuritzkes, D; Madinger, N; Schooley, R; Mass, A; Hofflin, JM; Britton, K; Blum, R; Cott, G; Golub, B; Greenberg, K; Lichtenstien, K; O'Brien, R; Motley, RF; Culliman, M; Fujeta, N; Mason, S; McLeod, GX; Mateos-Mora, M; Demers, D; Jackson, C; Zar, B; Ramakrishna, B; Jones, CL; Lucht, W; Conrad, S; Grier, LR; King, JW; Adelso, J; Kim-Karpe, M; Bergman, M; Schut, R; Sterling, T; Brewer, JH; Anderson, DE; Roehrs, J; Dietrich, JE; Jones, D; Ward, C; Stockfish, JF; Allen, S; Crowell, RE; Cushing, A; Goade, D; Irizarry, L; Jenison, S; Levy, H; Overturf, G; Palmer, D; Quenzer, R; Reed, W; Simpson, S; Williams, J; Berger, BJ; Hussain, F; Berger, B; Sepe, F; Hargreaves, J; Baddour, LM; Parrish, R; Plemmons, R; Radolf, J; Szeyko, G; Elkind, K; Knight, V; Badger, MS; Furlan, J; Gillum, M; Tice, AD; Barany, J

doi:10.1177/135965359900400404

Public

Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience

Shared by NobleBlocks on May 1, 1999 • 12:00 AM UTC

Authors:

Louisa E Chapman

Gregory J Mertz

Clarence J Peters

Abstract

Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because...

Discussions